Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
NCT02608450 is registered in ClinicalTrials.gov with Cassiopea SpA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
- Lead sponsor
- Cassiopea SpA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 21, 2016
- Completion date
- April 11, 2018
- Enrollment
- 708 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.